Evidence map›Paper›PMID 41865684›Full record

ArticleInternational journal for parasitology. Drugs and drug resistance2026

TRPtracker: a community database for monitoring praziquantel sensitivity at TRPM

Claudia M Rohr, Sang-Kyu Park, Kelsilandia Aguiar-Martins, Timothy J C Anderson, Duncan J Berger, Matthew Berriman, Sarah K Buddenborg, Amaya L Bustinduy, Frédéric D Chevalier, James A Cotton and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal for parasitology. Drugs and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors.

Claudia M RohrDepartment of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee, WI, USA.
Sang-Kyu ParkDepartment of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee, WI, USA.
Kelsilandia Aguiar-MartinsDepartment of Pathobiology and Population Sciences, Royal Veterinary College, University of London, Herts, UK.
Timothy J C AndersonTexas Biomedical Research Institute, San Antonio, TX, USA.
Duncan J BergerWellcome Sanger Institute, Hinxton, Cambridgeshire, UK.
Matthew BerrimanSchool of Infection and Immunity, College of Medicine, Veterinary and Life Sciences, University of Glasgow, UK.
Sarah K BuddenborgWellcome Sanger Institute, Hinxton, Cambridgeshire, UK.
Amaya L BustinduyDepartment of Clinical Research, London School of Hygiene & Tropical Medicine, Keppel Street, London, UK.
Frédéric D ChevalierTexas Biomedical Research Institute, San Antonio, TX, USA.
James A CottonSchool of Biodiversity, One Health and Veterinary Medicine, College of Medicine, Veterinary and Life Sciences, University of Glasgow, UK.
Thomas CrellenSaw Swee Hock School of Public Health, National University of Singapore, Singapore.
Stephen R DoyleWellcome Sanger Institute, Hinxton, Cambridgeshire, UK.
Aidan M EmeryScience Department, Natural History Museum, London, UK.
Julien Kincaid SmithCBGP, IRD, CIRAD, INRAE, Institut Agro, Université de Montpellier, Montpellier, France.
Safari Kinung'hiNational Institute for Medical Research (NIMR) Mwanza Centre, P.O Box 1462, Mwanza, the United Republic of Tanzania.
Poppy H L LambertonSchool of Biodiversity, One Health and Veterinary Medicine, College of Medicine, Veterinary and Life Sciences, University of Glasgow, UK.
Winka Le Clec'hTexas Biomedical Research Institute, San Antonio, TX, USA.
Eric NdombiDepartment of Medical Microbiology and Parasitology, Kenyatta University, Nairobi, Kenya; Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.
Tom PennanceScience Department, Natural History Museum, London, UK.
Candia RowelVector Borne & Neglected Tropical Disease Control Division, Ministry of Health, Kampala, Uganda.
Shannan S SummersDepartment of Clinical Research, London School of Hygiene & Tropical Medicine, Keppel Street, London, UK.
John Vianney TushabeDivision of Biomedical Engineering, University of Glasgow, Glasgow, UK.
Martin WalkerDepartment of Pathobiology and Population Sciences, Royal Veterinary College, University of London, Herts, UK; Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, White City Campus, London, UK.
Bonnie L WebsterScience Department, Natural History Museum, London, UK.
Joanne P WebsterDepartment of Pathobiology and Population Sciences, Royal Veterinary College, University of London, Herts, UK; Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London, White City Campus, London, UK.
Shona WilsonDepartment of Pathology, University of Cambridge, Cambridge, UK.
Jonathan S MarchantDepartment of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee, WI, USA. Electronic address: JMarchant@mcw.edu.

Funding

Genetic Basis of Praziquantel ResistanceR01AI123434 · NIAID · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI ANDERSON, TIM J, LOVERDE, PHILIP T · 2016 to 2020
$3.5M
Genomic consequences of schistosome hybridizationR01AI166049 · NIAID · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI ANDERSON, TIM J · 2021 to 2025
$3.1M
Resolving the properties of schistosome TRPMPZQ, the target of the anthelmintic drug praziquantelR01AI145871 · NIAID · MEDICAL COLLEGE OF WISCONSIN · PI Wei Liu, JONATHAN S MARCHANT · 2020 to 2026
$3.1M
Characterisation of drug resistance in field-collected schistosomesR01AI160433 · NIAID · KENYATTA UNIVERSITY · PI NDOMBI, ERIC MAKUTO · 2021 to 2025
$786k
Functional interrogation of parasitic flatworm TRPM channels to identify novel anthelminticsF31AI183573 · NIAID · MEDICAL COLLEGE OF WISCONSIN · PI Claudia M Rohr · 2024 to 2026
$149k
NIAID NIH HHS F31 AI183573NIAID NIH HHS R01 AI123434NIAID NIH HHS R01 AI145871NIAID NIH HHS R01 AI160433NIAID NIH HHS R01 AI166049Wellcome TrustWellcome Trust 104958/Z/14/Z
6 · The paper itself

Abstract

The anthelmintic praziquantel (PZQ) has been used for decades as the clinical therapy for schistosomiasis, and remains the only available drug. As a cheap and effective drug therapy for all human disease-causing Schistosoma species, usage of PZQ underpins mass drug administration strategies aimed at eliminating schistosomiasis as a public health problem by 2030. Concern over the potential emergence of resistance to PZQ is therefore warranted, as it would constitute a major threat to this approach. In terms of molecular adaptations conferring PZQ resistance, variation in the sequence and/or expression of the drug target is an obvious mechanism and should be a priority for surveillance efforts. The target of PZQ is a transient receptor potential ion channel, TRPM

Indexed as

AnthelminticsDrug ResistancePraziquantelSchistosomaTransient Receptor Potential ChannelsAnimalsHumansAnthelminticsPraziquantelTransient Receptor Potential ChannelsDatabaseResistanceSchistosomiasisTransient receptor potential channel

Identifiers

PMID41865684
PMCPMC13020021

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.